Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07468604) titled 'Cervicothoracic Sympathetic Block Evaluation for Post COVID Condition' on Feb. 26.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: University Health Network, Toronto

Condition: Autonomic Dysfunction

Intervention: Drug: 5 mL of 0.25% bupivacaine with epinephrine (1:200,000)

Recruitment Status: Not recruiting

Phase: Phase 4

Date of First Enrollment: April 1, 2026

Target Sample Size: 78

To know more, visit https://clinical...